OncoMatch/Clinical Trials/NCT05825443
Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
Is NCT05825443 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Camrelizumab for immunotherapy.
Treatment: Camrelizumab — Postoperative adjuvant chemotherapy followed by immunotherapy for non-small cell lung cancer has become a new treatment recommendation, but there are still many clinical problems to be solved in postoperative adjuvant immunotherapy. This study aims to explore the efficacy and safety of adjuvant chemotherapy combined with immunotherapy in patients with stage IIA-IIIA non-small cell lung cancer after surgery. Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity.
Check if I qualifyExtracted eligibility criteria
Disease stage
Required: Stage IIA, IIB, IIIA (TNM)
the TNM stage after surgery is IIA-IIIA
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: surgical resection — curative
patients with non-small cell lung cancer who have undergone surgical resection
Cannot have received: chemotherapy
Have not received any chemotherapy for non-small cell lung cancer before enrollment
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 109/l, platelet count ≥ 100 × 109/l, hemoglobin ≥ 9g/dl
Kidney function
serum creatinine ≤ 1.25 uln, or serum creatinine clearance ≥ 60ml/min
Liver function
total bilirubin ≤ 1.5 uln; ast and alt ≤ 2.5 uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify